LB Pharmaceuticals appoints Susan Kozauer as Chief Medical Officer; $515k base, NOVA-2 readout H1 2027

LB PHARMACEUTICALS INC

Appointed Susan G. Kozauer, M.D. as CMO effective Sept 14, 2026; previously SVP at Centessa and VP at Intra-Cellular.
Compensation: $515k annual base salary, 40% target bonus, $150k sign-on bonus, and 200,000-share option vesting over 4 years.
CEO Heather Turner cites Kozauer's expertise as pivotal for Phase 3 NOVA-2 topline results in schizophrenia expected H1 2027.
Kozauer led clinical development of CAPLYTA across schizophrenia, bipolar disorder, and MDD, resulting in multiple FDA approvals.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Susan G. Kozauer

Chief Medical Officer

LBRX · LB PHARMACEUTICALS INC

Effective: 2026-09-14
Filed: September 15, 2026, 8:05 AM ET

On September 15, 2026, LB Pharmaceuticals Inc (the “Company”) announced that Susan G. Kozauer, M.D. has been appointed to serve as the Company’s Chief Medical Officer, effective as of September 14, 2026 (the “Start Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Susan G. Kozauer was appointed as Chief Medical Officer at LB PHARMACEUTICALS INC.

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On September 15, 2026, LB Pharmaceuticals Inc (the “Company”) announced that Susan G. Kozauer, M.D. has been appointed to serve as the Company’s Chief Medical Officer, effective as of September 14, 2026 (the “Start Date”).

View on SEC.gov

LB PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001193125-26-391358

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.